ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Tidal Trust II Defiance Daily Target 2x Long MSTR ETF

Tidal Trust II Defiance Daily Target 2x Long MSTR ETF (MSTX)

101.98
9.37
(10.12%)
Closed November 12 4:00PM
99.83
-2.15
( -2.11% )
Pre Market: 7:33AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
99.83
Bid
99.70
Ask
100.05
Volume
126,207
0.00 Day's Range 0.00
15.18 52 Week Range 104.00
Previous Close
101.98
Open
-
Last Trade
4
@
99.92
Last Trade Time
07:34:15
Average Volume (3m)
4,159,876
Financial Volume
-
VWAP
-

MSTX Latest News

Bitcoin Surges as US PCE Drops; MicroStrategy ETFs See Rising Investor Demand, and Latest in Crypto

Bitcoin reacts to PCE data Bitcoin (COIN:BTCUSD) reached an intraday high of $66,550 on Friday and is currently trading at $65,566, a 0.6% increase over the past 24 hours. This rise followed the...

NYSE and Nasdaq Pull ETF Options Requests, 75% of Bitcoins Remain Inactive, MakerDAO Halts WBTC Loans

New York Stock Exchange and Nasdaq withdraw crypto ETF options listing requests The NYSE and Nasdaq International Securities Exchange have withdrawn three requests to list options for Bitcoin and...

Deutsche Bank Faces Shareholder Backlash, Bank of America Sponsors 2026 World Cup, Quanterix CEO Buys More Shares

Deutsche Bank (NYSE:DB) – Deutsche Bank has proposed a settlement to resolve shareholder lawsuits alleging that the bank underpaid for the Postbank acquisition. However, shareholders’...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
144.0378.906810035855.810450.1608540180.45660054SP
461.83162.7105263163810433.25433123258.93605711SP
1278.83375.3809523812110415.18415987637.93251151SP
2679.18383.43825665920.6510415.18402165837.39912752SP
5279.18383.43825665920.6510415.18402165837.39912752SP
15679.18383.43825665920.6510415.18402165837.39912752SP
26079.18383.43825665920.6510415.18402165837.39912752SP

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MVSTMicrovast Holdings Inc
$ 0.42005
(132.46%)
41.01M
ESLAEstrella Immunopharma Inc
$ 1.21
(51.82%)
101
KXINKaixin Holdings
$ 4.23
(44.86%)
3.14M
NMHINatures Miracle Holding Inc
$ 0.1219
(42.24%)
38.01M
DAVEDave Inc
$ 84.50
(34.55%)
65.97k
SYRSSyros Pharmaceuticals Inc
$ 0.4599
(-83.15%)
6.26M
VINOGaucho Group Holdings Inc
$ 2.48
(-44.27%)
8.42k
SIDUSidus Space Inc
$ 1.33
(-40.89%)
654.03k
LBTYALiberty Global Ltd
$ 12.75
(-38.52%)
11
VRMVroom Inc
$ 5.71
(-35.63%)
5.21k
MVSTMicrovast Holdings Inc
$ 0.42005
(132.46%)
41.01M
NMHINatures Miracle Holding Inc
$ 0.1219
(42.24%)
38.01M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 20.465
(3.83%)
7.02M
SYRSSyros Pharmaceuticals Inc
$ 0.4599
(-83.15%)
6.26M
ELABElevai Labs Inc
$ 0.0194
(3.19%)
6.04M

MSTX Discussion

View Posts
Mikey Mikey 2 months ago
New board..........MSTX............Pay attention here!
👍️0
lux1 lux1 8 years ago
new discussion board after the merger MSTX SVRA : https://investorshub.advfn.com/Savara-SVRA-32068/
👍️0
someconcerns someconcerns 8 years ago

Savara Announces Closing Of Merger With Mast Therapeutics

Commences Trading on Nasdaq Capital Market on April 28, 2017 Under Ticker Symbol "SVRA"

Conference Call Scheduled for Tuesday May 2nd, 2017 at 4:30 p.m. ET / 3:30 p.m. CT
Savara Inc. (PRNewsfoto/Mast Therapeutics)

News provided by
Savara Inc.

16:15 ET

Share this article

AUSTIN, Texas, April 27, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the closing of its previously announced merger with Mast Therapeutics, Inc. (NYSE MKT: MSTX), under which the stockholders of Savara have become the majority owners of Mast, and the operations of Mast and Savara have combined. The post-merger company, named Savara Inc., is based in Austin, TX and features three inhaled product candidates, each in advanced stages of clinical development. The company will be led solely by Savara's current management team. Two independent members of the Mast board remain on the post-merger board together with all five members of the Savara board. Savara's common stock will commence trading on April 28th, 2017 on the Nasdaq Capital Market under the trading symbol "SVRA".

"Savara's transition to the public market marks a significant milestone for us, and serves as testament to the determination of our team as well as the support of our investors to date," stated Rob Neville, Chairman and CEO of Savara. "Savara's team is passionate about helping those who suffer from rare and debilitating lung diseases and will dynamically pursue opportunities to develop impactful products to treat such conditions. We believe Savara presents an attractive business opportunity with our pipeline of unique products with considerable market potential, as well as significant value-driving clinical milestones."

Savara began the development of AeroVanc in 2010 and is now in preparation for a pivotal Phase 3 study. In July 2016, Savara acquired Serendex Pharmaceuticals adding Molgradex to its pipeline. Molgradex is currently in Phase 2/3 development. With the closing of the Mast merger, Savara adds the Aironite program to its pipeline (also known as AIR001). Savara intends to continue its growth strategy focused on indication expansion, strategic development partnerships and product acquisitions.

In connection with the closing of the merger, Mast effected a 1 for 70 reverse split of its common stock. Post-merger and post-reverse split, Savara has approximately 15 million shares of common stock issued and outstanding with prior Savara stockholders collectively owning approximately 77% of the combined company, and prior Mast stockholders collectively owning approximately 23% of the combined company. Prior to the merger closing, Savara stockholders exercised certain previously issued warrants to purchase Savara shares and invested additional capital into the company, resulting in aggregate net proceeds of approximately $4 million.

Savara's pipeline now includes:

Molgradex, an inhaled nebulized GM-CSF to treat pulmonary alveolar proteinosis (PAP) currently in Phase 2/3 development;
AeroVanc, an inhaled dry-powder vancomycin to treat chronic methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection in cystic fibrosis (CF) in preparation for a pivotal Phase 3 study; and
Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction (HFpEF) currently in Phase 2 development.

Select Development Milestones

Completing negotiations with the U.S. Food and Drug Administration (FDA) on the requirements for a pivotal clinical study of Molgradex in the U.S. in Q2/2017;
Initiating a pivotal Phase 3 study of AeroVanc in Q3/2017;
Announcing an indication expansion strategy of Molgradex for the treatment of a rare lung infection in Q3/2017;
Announcing top-line results from a Phase 2/3 study of Molgradex, expected to be registration-enabling in Europe and Japan, in Q1/2018; and
Announcing results from an ongoing Phase 2 study of Aironite being conducted by the Heart Failure Clinical Research Network in H1/2018.

Conference Call and Webcast

Savara will hold a conference call on Tuesday May 2nd, 2017, at 4:30 p.m. Eastern Time / 3:30 p.m. Central Time to provide an overview and business update. Interested parties may access the conference call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from outside the U.S. and should request the Savara Inc. Call. A live webcast of the conference call will be available online from the Investors section of Savara's website at http://www.savarapharma.com/investors/events/. Replays of the webcast will be available on Savara's website for 30 days and a telephone replay will be available through May 9th, 2017 by dialing (877) 344-7529 from the U.S., (855) 669-9658 from Canada, and (412) 317-0088 from elsewhere outside the U.S. and entering replay access code 10104600.
👍️0
lux1 lux1 8 years ago
the Mast nightmare's over: merger closed . From tomorrow the ticker will be SVRA and the CEO Neville
👍️0
lux1 lux1 8 years ago
management of the merger in Culley's style: awful, as usual
👍️0
TheKobra TheKobra 8 years ago
Last hour of MSTX?
👍️0
lux1 lux1 8 years ago
pain for long until Culley is the CEO , also the last day or even the last hours.
👍️0
nycusa12 nycusa12 8 years ago
The website is up and runing i have no problem getting into the site ,,
👍️0
nycusa12 nycusa12 8 years ago
I would guess they will put out the news after hours ,i am hoping for blow out for a change DREAM BABY GO M $ T X ..........
👍️0
TheKobra TheKobra 8 years ago
The website is out of service! Mmm
👍️0
TheKobra TheKobra 8 years ago
Any news from the special meeting?
👍️0
nycusa12 nycusa12 8 years ago
Dreams Due come true sometimes lets hope and dream that this is one of them , Go M $ T X ,,,,
👍️0
Basaria Basaria 8 years ago
Two things:

1. The increased price if the merger is approved will dilute the retail price. There will be initial pull back.
2. Reverse mergers are 90% plus ineffective.

But in saying that, I wish all of you luck. Penny's are def hard, so the longs deserve this :)
👍️0
nycusa12 nycusa12 8 years ago
OHH YES new high of the day,,,,,,, i guess someone knows something that we don't know yet ,,,,,,,,,,next we need to break the .1490 mark,,,, LET'S GOOO
👍️0
TheKobra TheKobra 8 years ago
Go $mstx let us dream
👍️0
nycusa12 nycusa12 8 years ago
Break that .1432 high of the day
👍️0
nycusa12 nycusa12 8 years ago
Don't look back baby .........
👍️0
nycusa12 nycusa12 8 years ago
OHH YES .14 down keep climbing baby
👍️0
nycusa12 nycusa12 8 years ago
come on Break that 14 mark
👍️0
nycusa12 nycusa12 8 years ago
I guess so , might go KABOOOOM
👍️0
pray pray 8 years ago
Seems like traders waiting for some kind of update before buying or selling ....
👍️0
TheKobra TheKobra 8 years ago
We have to break the resistance wall @.14!!!
👍️0
Cicant Cicant 8 years ago

http://masttherapeutics.com/investors/news/?releaseid=2264376
👍️0
lux1 lux1 8 years ago
I hope they are calling all the shareholders that have not yet voted. Still 2 days to vote
👍️0
lux1 lux1 8 years ago
I get that feeling too. The vote has been poorly managed: quite late and inadequately. I hear some votes had not been recorded or not entirely,they did it only after voters recalled.
If it doesn't pass there's a possibility of lawsuit.
👍️0
wellfed wellfed 8 years ago
Even though I have position in this, I can understand where you are coming from.

Only way MSTX will benefit at this point in my opinion is a buyout not a merger.


Trying to recoup my money and bounce.
👍️0
pray pray 8 years ago
Really hope I am wrong, but IMO Cully does not desire merger either. He is just seeking to cover bases because of lawsuits. Then he will began suckering new investors.
👍️0
b1d b1d 8 years ago
I feel like Hillary watching the election results, remembering the popular vote doesnt mean sh*t.
👍️0
wellfed wellfed 8 years ago
I'd hate to admit, but after the merger news got pushed back to Thursday, I am beginning to doubt if this company has any more left in them to go farther. I am exiting hopefully tomorrow when it bounce.
👍️0
pray pray 8 years ago
If you define good by management benefits, share options, salary increase's you are absolutely correct.

If you have been a shareholder here you can not really see any benefit to this stock. RS, 4 offerings, dilution, share count tripling in last 7 years. Add to that nothing but 5 failed drug tests in 7 years with 5 new drugs. If you invested $100 7 years ago, management has absorbed all but a dime.

In all fairness can you share one benefit a long shareholder has experienced?

Even management could not plan a successful merger. Thus far along with every "botched" test they could not achieve one simple goal .... merger. The 90% voting are not voting for merger, RS, or name change. They are voting to get rid of management in a worthless CEO Cully ....period.
👍️0
ClayTrader ClayTrader 8 years ago
* * $MSTX Video Chart 04-21-17 * *

Link to Video - click here to watch the technical chart video

👍️0
CrazyKar123 CrazyKar123 8 years ago
No not really . MSTX good company been I have had for 15 years I would recommend buy .
👍️0
lux1 lux1 8 years ago
Thank you pray.
The nightmare continues, let's hope it's only for a few days.
👍️0
pray pray 8 years ago
Have spoken to Cully personally twice. He is the type that covers bases for that reason. He know how to take advantage of both shareholders as well as institutions, he has made a life from it.

In the case of Savara, he knows Neville has both character and integrity, two items Cully knows nothing about. Rather than drag a company through needless court costs I personally feel Neville would just walk away to save shareholders money and not wasting time. Cully knowing that has set his scheme into motion. If vote passes he gets bonus and praise, it fails Savara walks away with no major losses. In the second case Cully will wine that shareholders just would not get out to vote, not his fault.

Remember management could also care less about shareholders. Cully has rewarded them with bonuses, options and everything at the cost of shareholders. They will never get rid of Cully, that worthless piece of trash.

It has been several years but I stated when Cully added Air it was because he knew EPIC would fail and he could proclaim "we still have a possible Multi Million Dollar Drug" in pipeline with cash. Well it ended just as I predicted. Epic had a 70-80% success rate by Cully, and after failure no follow up why failure? Why Cully knew failure from start. He controlled it.

Cully is the lowest of scum. He is puse of inner cancer hiding itself until it is to late. There was a "Rodney" on this board couple years back that controlled the boards by deleting any non praise of Cully or Mast. Cully mentioned his name in our second conversation. I personally believe he was employed by Mast to pump Cullys schemes.
👍️0
Masala Masala 8 years ago
I think after today MSTX becomes a going concern with a likely selling of assets and a breakup of MSTX
👍️0
lux1 lux1 8 years ago
If this time Cully screws over Savara, Neville and investors will take him to court.
👍️0
Woulfe Woulfe 8 years ago
Your definitely right about that. I've been watching Mstx from the sidelines out of curiosity ever since I sold a year ago for a decent profit. Mstx is a cash cow to culley, he doesn't care about shareholder value. If the merger doesn't pass Airs will be just another excuse for him to continue this cycle all over again. R/s, dilution, selling false hope. He needs to be replaced.
👍️0
pray pray 8 years ago
Cully screws up again. Seven years ago institutional investment was at 53%. You would not even need shareholders, just institutions vote but because of Cullys first RS, dilution, yearly offering, and share count doubling every year Cully can not even get enough votes for merger.

Five failed drug tests in 5 tries in seven years. Over 95% of votes for merger. Do not believe the lie. The 95% are voting to get rid of this worthless advertisement for a CEO that has taken a dollar invested and given shareholders just over a dime in return.
👍️0
kpisme kpisme 8 years ago
Let's get out there and VOTE

https://seekingalpha.com/news/3258312-shareholders-back-mast-therapeutics-merger-savara-quorum-yet-tomorrows-special-meeting#email_link

👍️0
bigarow bigarow 8 years ago
Buys to sells. = 6 to 4.Once people understand progress MSTX is making they will come aboard in numbers.Do your DD this is a winner.
👍️0
bigarow bigarow 8 years ago
That's a plus for us.It scares some novice buyers and give us time to load up.Wich I did this am In the green already.All I can say is WOW.When this merger takes place we fly.IMO
👍️0
lux1 lux1 8 years ago
To date the 44% voted,still not enough to reach the quorum (50% + 1), that are 112 million share-votes out of 255 million shares entitled.
There are therefore 143 million shares without vote, and about 15 million of votes (6%) are still needed for the quorum, likely some hundreds of voters.
I'm not worried because this is not a mission impossible by Friday and surely easy by next week, but Culley's organisation has once again failed!


http://masttherapeutics.com/investors/news/?releaseid=2263203
👍️0
pray pray 8 years ago
See your point, would not put it past Culley to somehow screw this up. That is what he is great at.

Read this today .....

"Mast Therapeutics reminds shareholders to vote for the proposed merger with Savara; of the votes received to date, more than 90% are voting in favor of the mergerFont

"The overwhelming majority of Mast stockholders who have submitted their votes have voted in favor of the merger.

However, more votes are needed to meet the required threshold for the merger to be completed," stated Brian M. Culley, Chief Executive Officer of Mast."
👍️0
acnyc acnyc 8 years ago
Point noted Masala. I respect and understand your decision. Wish you luck and hope we both make a little some some in the weeks to come!
👍️0
Masala Masala 8 years ago
For me selling makes sense, buying back after the split and after the price has stabilized...
👍️0
acnyc acnyc 8 years ago
Lux1, you make a good and correct point about the R/S. Unfortunately, people don't get the entire R/S thing and assume they are all bad. I've had luck with Reverse Splits in the past, and assuming this merger gets approved , , , it will have a positive effect.
👍️0
lux1 lux1 8 years ago
At this point the split ratio is irrelevant. Do you prefer 1 billion shares at one Cent or 10 million shares at one dollar?
It is the same as changing coins in notes, actually a lower float is surely positive for the PPS. In any case it is needed by NYSEMKT rules of the merger that requires 4 or 5 dollar minimum.
Let's think instead of the very positive effects of the merger on this devastated Company: a new pipeline with 3 drugs added and not last a new CEO.
👍️0
Masala Masala 8 years ago
Out today at 1:50 or 1:70 split it doesn't make sense to hold the shares, failure of merger is kind of a scary thought too.....best of luck
👍️0
lux1 lux1 8 years ago
the R/S PPS should be $8-$10, to satisfy the AMEX rules of the merger and to attract institutional investors and funds, most of them have $5 as lower limit to invest in the NASDAQ stocks.
IMO
👍️0
AKAPAK AKAPAK 8 years ago
Again, appreciate your response. I have poked around for the info, but not as much to get to thee numbers.

B/R
👍️0

Your Recent History

Delayed Upgrade Clock